Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial

Universitätsklinikum Hamburg-Eppendorf · 2021
ClinicalTrials.gov · Datasets · License: Public Domain · 2021
Open Source ↗
relapsing-remitting multiple sclerosis, autologous hematopoetic stem cell transplantation, alemtzumab, ocrelizumab, randomised controlled trial, aggressive highly active multiple sclerosis, no evidence of diseae activity (neda), interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 825544
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.